For the development of a neutralizing antibody-based human immunodeficiency virus type 1 (HIV-1) vaccine, it is important to characterize which antibody specificities are most effective against currently circulating HIV-1 variants. We recently reported that HIV-1 has become more resistant to antibody neutralization over the course of the epidemic, and we here explore whether this increased neutralization resistance is also observed for the newly identified broadly neutralizing antibodies (BrNAbs) PG9, PG16, and VRC01. Furthermore, we performed a comprehensive analysis of the neutralizing sensitivity of currently circulating recently transmitted subtype B viruses to the currently most known BrNAbs. Virus variants isolated less than 6 months after seroconversion from individuals who seroconverted between 2003 and 2006 (n ‫؍‬ 21) were significantly more resistant to neutralization by VRC01 than viruses from individuals who seroconverted between 1985 and 1989 (n ‫؍‬ 14). In addition, viruses from contemporary seroconverters tended to be more resistant to neutralization by PG16, which coincided with the presence of more mutations at positions in the viral envelope that may potentially influence neutralization by this antibody. Despite this increased neutralization resistance, all recently transmitted viruses from contemporary seroconverters were sensitive to at least one BrNAb at concentrations of <5 g/ml, with PG9, PG16, and VRC01 showing the greatest breadth of neutralization at lower concentrations. These results suggest that a vaccine capable of eliciting multiple BrNAb specificities will be necessary for protection of the population against HIV-1 infection.
It is generally assumed that the most effective way to control the AIDS epidemic will be the use of a vaccine that protects against human immunodeficiency virus type 1 (HIV-1) infection (14) . For most viruses, neutralizing antibodies (NAbs) elicited by currently available vaccines are a correlate of protection (2, 34) . Passive immunization was shown to confer protection against simian immunodeficiency virus (SIV) infection in macaque models (3, 19, 27, 28, 33, 49) , suggesting that preexisting humoral immunity may also be able to prevent HIV-1 infection. However, the development of an effective NAb-based vaccine has been hampered by the huge sequence variability of HIV-1 isolates. An important focus of vaccine design is therefore the identification and characterization of antibody specificities that are effective against the majority of currently circulating HIV-1 variants in order to use their epitopes for immunogen design (9) . However, the mimicking of epitopes of cross-reactive neutralizing antibodies in an immunogen have met only very limited success (29) .
During natural HIV-1 infection, NAbs against autologous viral strains are not detectable until approximately 2 months or later after transmission (1, 11, 16, 31, 32, 36, 37, 45, 51) . Two of the factors involved in this delayed development of NAbs are the massive depletion of CD4 ϩ T cells and the destruction of germinal centers in the gut during acute HIV-1 infection (25, 48) . This early loss of germinal centers may have an effect on the generation of early high-affinity HIV-1-specific NAbs. Nevertheless, a substantial proportion of HIV-infected individuals (ϳ30%) is able to mount NAb responses against a wide range of heterologous HIV-1 variants after 2 to 3 years of infection (12, 13, 41) . Thus far, several rare potent monoclonal antibodies (MAbs) with broadly HIV-specific neutralizing activities have been isolated from such individuals.
Until recently, only a small number of broadly neutralizing antibodies (BrNAbs) with relatively subtype-specific neutralization patterns had been identified: CD4 binding site-directed MAb b12, glycan-binding MAb 2G12, and gp41-directed MAbs 2F5 and 4E10 (5) . Although studies of macaques suggest that low titers of these MAbs should be sufficient to block infection (19, 20, 21) , it has been shown that some viruses are resistant to neutralization by multiple BrNAbs (5, 8, 35) . We can therefore assume that these antibody specificities are too narrow to confer protective immunity against global HIV-1. In contrast, the recently discovered MAbs PG9 and PG16, binding mainly to a quaternary epitope on the second variable loop in the viral envelope trimer (50) , and MAb VRC01, directed at the CD4 binding site (54) , display a greatly enhanced breadth of neutralization and potency compared to earlier BrNAbs.
In a previous study, we reported that HIV-1 has become more resistant to antibody neutralization over the course of the epidemic (7) . In that study, HIV-1 variants isolated from individuals who seroconverted in recent years, compared to viruses isolated from individuals who seroconverted early in the epidemic, showed a decreased sensitivity to polyclonal antibodies (i.e., human serum and HIV-Ig) and to MAb b12 but not to MAb 2G12, 2F5, or 4E10. We here extend those findings by investigating whether this adaptation of HIV-1 to antibody neutralization also affects the neutralizing activity of the recently identified BrNAbs PG9, PG16, and VRC01. In addition, we provide a comprehensive overview of the breadth and potency of the currently known BrNAbs (b12, 2G12, 2F5, 4E10, PG9, PG16, VRC01) and TriMab (a 1:1:1 mixture of b12, 2G12, and 2F5) against recently transmitted HIV-1 variants from contemporary seroconverters. Our results show that while HIV-1 has become more resistant to CD4 binding sitedirected neutralization and possibly also to neutralization by PG16 over the course of the epidemic, all virus variants were sensitive to at least one of the BrNAbs tested. Our observations suggest that a vaccine will need to elicit broadly neutralizing antibodies of multiple specificities in order to protect against the large majority of currently circulating HIV-1 strains.
MATERIALS AND METHODS
Subjects and viruses. The "historical" and "contemporary" seroconverters included in this study (Table 1) were persons with an acute or early subtype B HIV-1 infection and a known seroconversion (SC) date either between 1985 and 1989 (n ϭ 14) or between 2003 and 2006 (n ϭ 21), most of whom were also included in a previous study (7) . Historical HIV-1-infected individuals participated in the Amsterdam Cohort Studies on HIV Infection and AIDS (ACS) and seroconverted during active follow-up, exhibiting a documented HIV-1-negative test result 180 days prior to seroconversion. Contemporary seroconverters were seen at the HIV outpatient clinic of the Academic Medical Center in Amsterdam, the Netherlands, and had laboratory evidence of a primary HIV-1 infection, defined as a positive plasma HIV-1 RNA or p24 antigen test, in combination with a negative test for HIV-1-specific antibodies or an indeterminate Western blot result.
Clonal HIV-1 variants were obtained from cryopreserved peripheral blood mononuclear cells (PBMC) according to previously described methods (40, 47) . For all virus variants studied here, CCR5 usage was predicted by the V3 loop sequence using position-specific scoring matrix (PSSM) (22) and confirmed by the inability of these viruses to replicate in the MT-2 cell line.
This study has been conducted in accordance with the ethical principles set out in the Declaration of Helsinki, and written informed consent was obtained from each participant prior to data and material collection. The study was approved by the Academic Medical Center's institutional Medical Ethics Committee.
Neutralization assay. Primary HIV-1 isolates were tested for their neutralization sensitivity (i) against monoclonal antibodies b12 (kindly provided by D. 50 ) in a volume of 100 l was incubated for 1 h at 37°C with 2-or 3-fold serial dilutions of monoclonal antibody. The highest antibody concentrations tested were based on known neutralization titers and varied per MAb. PG9 and PG16 were analyzed in the range of 16 ng/ml to 1 g/ml, VRC01 was analyzed in the range of 78 ng/ml to 5 g/ml, and b12 was analyzed in the range of 0.19 g/ml to 12.5 g/ml, while 2F5, 4E10, 2G12, and TriMab were tested in the range of 0.39 g/ml to 25 g/ml.
Subsequently, the mixtures of virus with antibody or serum were added to 10 5 phytohemagglutinin (PHA)-stimulated PBMC in 50 l medium. Virus production in culture supernatants on days 7 to 11 (depending of viral growth) was analyzed by an in-house p24 antigen capture enzyme-linked immunosorbent assay (ELISA) (44) . Experiments were performed in triplicate. The percent neutralization was calculated by determining the reduction in p24 production in the presence of neutralizing agent compared to the levels of p24 in the cultures with virus only. When possible, 50% inhibitory concentrations (IC 50 s) were determined by linear regression. For calculations, viruses with IC 50 s lower than the lowest antibody concentration tested were assigned a value corresponding to the next dilution step (i.e., the lowest antibody concentration divided by 2 if 2-fold dilutions were used or by 3 if 3-fold dilutions were used), while viruses that did not reach 50% neutralization at the highest antibody concentration were assigned a value corresponding to the highest antibody concentration tested. Sequence analysis. Env of clonal HIV-1 variants isolated from participants was amplified from DNA that was isolated from in vitro-infected healthy donor PBMC. Env PCR products were subsequently sequenced as described previously (4, 6, 35) . Nucleotide sequences were aligned using ClustalW in the software package of BioEdit (17) and edited manually. For diversity calculations and phylogenetic tree construction, the variable regions were largely removed to allow reliable alignment of the sequences. Potential N-linked glycosylation sites (PNGS) were identified using N-GlycoSite (53) at the HIV database website (http://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html). The mean pairwise genetic diversity among viruses within each patient group was calculated under the Kimura two-parameter model in the software program MEGA version 5 (43), using the consensus sequence of all virus variants per patient.
Phylogenetic analysis. The matrix of aligned nucleotide sequences was imported into the tree-building software PAUP* (42) (http://paup.csit.fsu.edu/), and a neighbor-joining (NJ) tree (39) was constructed under the HasegawaKishino-Yano (HKY85) model of evolution (18) . The robustness of the NJ phylogeny was assessed by bootstrap analysis with 1,000 rounds of replication.
Heatmap analysis. A heatmap was made with a Web tool on the HIV database website (http://www.hiv.lanl.gov/content/sequence/HEATMAP/heatmap.html), which uses the heatmap tool heatmap.2 of the gplots package of the statistical environment R (a language and environment for statistical computing). Complete cluster analysis was performed on base10 data, and output was given as a heatmap with a 12-color "heat" palette. Viruses that did not reach 50% neutralization at the highest antibody concentration were assigned a value of 25, even if the highest antibody concentration tested for that particular BrNAb was lower than 25 g/ml. Bootstrap analysis was not performed, since the clustered groups were not further analyzed.
Statistical analysis. Statistical analyses were performed with the SPSS 17 software package. To compare IC 50 s between historical and contemporary viruses, the geometric mean (GM) IC 50 was calculated for all viruses per subject. Differences between both groups of viruses in geometric mean IC 50 s for monoclonal antibodies were evaluated using a Mann-Whitney U test. Differences in pairwise genetic diversity among both groups of viruses were evaluated using Student's t test.
Nucleotide sequence accession numbers. The sequences used in this study have been deposited in GenBank under accession numbers JF910158 to JF910276.
RESULTS
Sensitivities of recently transmitted HIV-1 variants from historical and contemporary seroconverters to neutralization by broadly neutralizing antibodies PG9, PG16, and VRC01. To extend our previous observation that, over the course of 20 years, HIV-1 has become more resistant to neutralization by BrNAb b12, HIV-Ig (24), and individual sera from HIV-1-infected individuals, we determined the sensitivities of recently transmitted HIV-1 variants from historical and contemporary seroconverters (Table 1) In agreement with our previous observation that HIV-1 over calendar time and at the population level has become more resistant to CD4 binding site-directed neutralizing activity, we observed a significant decrease in sensitivity to neutralization by the CD4 binding site-directed antibody VRC01 (Fig. 1A) between HIV-1 variants from historical and contemporary seroconverters. Due to the limited availability of VRC01, viruses from a small number of historical seroconverters, compared to the number of contemporary seroconverters, were tested for this antibody, but we still included the virus variants from all the individuals that were tested against b12 and HIV Ig in our previous study (7) . Although all viruses from historical sero- converters and most virus variants from contemporary seroconverters were sensitive to neutralization by VRC01 at concentrations below 5 g/ml, the median antibody concentration that conveyed 50% inhibition of virus replication (IC 50 ) was approximately 10-fold increased for viruses from contemporary seroconverters compared to that for viruses from historical seroconverters. In parallel with the results obtained with the CD4 binding site-directed antibodies b12 and VRC01, an increased proportion of currently circulating virus variants seemed to be resistant to neutralization by PG16 (Fig. 1B and  C) . The median IC 50 s of PG9 for viruses from historical and contemporary seroconverters were not significantly different, while a trend toward an increased neutralization resistance was observed for PG16 (P ϭ 0.053) (Fig. 1B and C) .
Molecular changes in HIV-1 envelope glycoprotein that potentially influenced the sensitivity to VRC01, PG9, and PG16.To investigate whether the decrease in the neutralizing sensitivity of HIV-1 to VRC01 over calendar time could be explained by changes in the molecular characteristics of the viral envelope, the gp120 sequences of viruses from historical and contemporary seroconverters were compared for known residue-by-residue contacts with CD4 and VRC01 as previously described (54) (Fig. 2A) . Although various amino acid substitutions were observed at these sites, there was no clear correlation between the sensitivity of the virus to VRC01 neutralization and the presence or absence of certain amino acids. Longer V5 loops were modestly correlated with increased resistance to neutralization by VRC01 (Spearman r ϭ 0.037, P ϭ 0.041), but As reported previously (50) , the absence of a potential Nlinked glycosylation site at position 160 in the V2 region coincided with resistance to both PG9 and PG16 neutralization at the highest antibody concentration tested (1 g/ml) (Fig. 2B) . In addition, multiple amino acid substitutions were observed at positions that were previously reported to affect the sensitivity of HIV-1 to neutralization by these two antibodies (50) (Fig.  2B) . Although we could not identify an association between the presence of certain mutations and a virus's sensitivity to PG9-and PG16-mediated neutralization, more mutations were observed at these positions in viruses from contemporary seroconverters than in viruses from historical seroconverters, which may explain the observed trend toward increased resistance to PG16 neutralization.
Genetic relationship between viruses from historical and contemporary seroconverters. The difference in neutralization sensitivity between viruses from historical and contemporary seroconverters as observed here could be biased by the relatively close genetic relationships between viruses within our local cohort. The diversity among viruses from historical seroconverters was lower than among viruses from contemporary seroconverters (6.2% and 13.2%, respectively; P Ͻ 0.0001) but reflected the change in the diversity of global subtype B HIV-1 viruses isolated within these time frames (7.2% and 12.9%, respectively; P Ͻ 0.0001). In addition, no support for the clustering of viruses from historical or contemporary seroconverters was obtained from phylogenetic analysis using either the neighbor-joining method (Fig. 3) or the maximum-likelihood method (data not shown), except with a cluster of five contemporary subjects (P195, P004, P151, P197, and P019). However, viruses within this cluster showed a broad spectrum of neutralization sensitivity for both VRC01 (IC 50 range, between 0.05 and 2.02 g/ml) and PG9/ PG16 (IC 50 range, between Ͻ0.02 and Ͼ1 g/ml), indicating that genetic relatedness among these viruses did not predict similarity in neutralization profiles.
Comparison of the activities of broadly neutralizing antibodies against recently transmitted contemporary HIV-1 variants. Our observations as described here and in our previous study (7) indicate that the neutralization sensitivity of HIV-1 has decreased over time but only to certain antibody specificities. To better understand the potential of currently known broadly neutralizing antibodies to neutralize currently circulating recently transmitted HIV-1 variants, we compared the activities of BrNAbs b12, 2G12, 2F5, 4E10, PG9, PG16, and VRC01 and of TriMab against HIV-1 variants that were isolated during primary HIV-1 infection from contemporary seroconverters.
To find patterns of neutralizing activity, we performed a clustering analysis based on the median IC 50 s of all viral variants per patient for every broadly neutralizing antibody. The results of this analysis are shown as a heatmap (Fig. 4) . The patients clustered in two separate groups based on their sensitivity to neutralization by PG9 and PG16, which had the most potent neutralization capacity compared to those of the remaining BrNAbs. The activities of these two antibodies were strongly correlated (Spearman r ϭ 0.88, P Ͻ 0.0001 [data not shown]), and viruses from all patients except P153 were either resistant or sensitive to both PG9 and PG16. However, all viruses that were resistant to neutralization by PG9 and PG16 were neutralized by two or more of the other BrNAbs tested.
The neutralizing activities of VRC01 and 4E10 were broadest in comparison to the those of the remaining BrNAbs, as all patients except P013 and P004 had HIV-1 variants that were sensitive to VRC01 and 4E10 neutralization, respectively. In contrast, a relatively large proportion of patients harbored viruses that were resistant to 2G12 and/or b12 neutralization, and for this reason 2G12 and b12 clustered apart from the other antibodies. Interestingly, the neutralizing activity profiles of 2G12 and b12 showed little similarity with that of TriMab. Instead, TriMab showed the highest neutralization correlation with 2F5 (Spearman r ϭ 0.46, P Ͻ 0.0001 [data not shown]), indicating that 2F5 may largely be responsible for the neutralizing activity of the antibody cocktail, at least against this panel of viruses. In addition, TriMab and 2F5 also clustered with 4E10, which is most likely the result of the proximal localization of the epitopes for these gp41-directed antibodies.
With the knowledge that HIV-1 is becoming more resistant to neutralization over the course of the epidemic, the question arises as to whether a vaccine that could elicit the currently known antibody specificities, either alone or in combination, would be sufficient to protect against currently circulating HIV-1 strains. As shown in the heatmap (Fig. 4) , none of the tested viruses were resistant to all antibodies at the tested antibody concentrations; in fact, the majority of virus variants were sensitive to multiple antibodies. However, at a low concentration of 1 g/ml, 19% of virus variants were resistant to all seven BrNAbs (data not shown).
Breadth and potency of broadly neutralizing antibodies at low concentrations against recently transmitted HIV-1 from contemporary seroconverters. Although it is still unclear how the in vitro neutralizing activity of a neutralizing antibody relates to its neutralizing potential in vivo, it is likely that a vaccine should elicit antibodies with broadly neutralizing activity at relatively low antibody concentrations. To further analyze the neutralization potency and breadth of each of the currently known BrNAbs, we determined the percentage of recently transmitted viruses from contemporary seroconverters that were neutralized by over 50% and over 90% by each BrNAb at concentrations of 1 g/ml and 5 g/ml, which are the approximate lower and upper borders for reported median IC 50 s for subtype B viruses of the various BrNAbs (5, 26, 50) ( Table 2 ). For individuals with multiple HIV-1 variants, we used the median IC 50 and IC 90 of all virus variants as single values for that subject.
The newly identified BrNAbs PG9, PG16, and VRC01 neutralized considerably more variants at the low concentrations than the well-known BrNAbs b12, 2F5, 2G12, and 2F5. When we consider the 50% neutralizing activities of BrNAbs at concentrations below 1 g/ml, PG16 showed the broadest activity, by neutralizing 57% of virus variants, followed by PG9 and VRC01, which neutralized 52% and 33% of viruses, respectively. The remaining antibodies were able to neutralize between 5% and 29% of virus variants. At the higher concentration of 5 g/ml, 4E10 and then VRC01 and 2F5 were the most broad in their neutralizing activities, neutralizing between 71% and 81% of viral variants, although it should be mentioned that the neutralizing activities of PG9 and PG16 were not tested at concentrations above 1 g/ml. The neutralizing activities of PG9 and PG16 were therefore potentially underestimated, as for some viruses 50% neutralization may have been achieved with BrNAb doses between 1 g/ml and 5 g/ml. The geometric mean IC 50 s across all HIV-1 variants were lower for the newly identified antibodies (all were Յ1 g/ml) than for the older BrNAbs (range, 2.5 to 6.8 g/ml). These new antibodies could also more stringently neutralize between 14 and 29% of transmitted viruses by over 90% at concentrations of less than 5 g/ml, whereas the older BrNAbs, with the exception of 2G12 and 2F5 (both of which neutralized only 5% of virus variants), could not neutralize any viral isolate by over 90% at this antibody concentration.
DISCUSSION
The recent discoveries of extremely broad and potent HIV-1-neutralizing antibodies, partially with novel epitope specificities, provide hope for the development of an NAb-based HIV-1 vaccine. However, we recently described the fact that HIV-1 has become more resistant to antibody neutralization over the course of 20 years of the epidemic (7). In our present study, we therefore analyzed the neutralizing activities of most currently known BrNAbs and, in particular, the antibodies PG9, PG16, and VRC01, which have recently been identified, against HIV-1 variants isolated during primary infection from historical seroconverters and from individuals who seroconverted in recent times.
The reduced sensitivity of viruses isolated from contemporary seroconverters to neutralization by VRC01 compared to that of HIV-1 variants from historical seroconverters confirms our previous observation that HIV-1 has become more resistant to CD4 binding site-directed neutralizing activity, including neutralization by b12. Interestingly, the neutralization activity profiles of VRC01 and b12 against our panel of viruses did not cluster in our heatmap analysis (Fig. 4) and were not correlated (data not shown), suggesting that resistance to neutralization by these antibodies may be conferred by distinct mechanisms, as previously suggested by others (52, 54) . In our previous study (7), we observed that the increased neutralization resistance of HIV-1 coincided with longer V1 regions and more potential N-linked glycosylation sites (PNGS) in that same region. These longer V1 loops may have been selected to mask underlying epitopes or to sterically hinder the access of neutralizing antibodies to the CD4 binding cavity. Apart from the CD4 binding region, the V5 loop is also involved in the interaction with VRC01 and is lodged between the heavy and light chains of the antibody (54) . More mutations downstream of V5, as observed in viruses from contemporary seroconvert- The sensitivity of HIV-1 to neutralization by PG16, in addition to the CD4 binding site-directed antibodies, seemed to have decreased, which coincided with an accumulation of mutations in HIV-1 Env that were previously described to interfere with neutralization by PG9 and/or PG16 (50) . This accumulation of mutations at the population level may be a direct consequence of selection pressure by PG9-and PG16-like antibodies. This observation may thus suggest that antibodies with PG9-and/or PG16-like specificities are elicited in a substantial proportion of HIV-1-infected individuals or that these escape mutations have been selected in rare individuals with these antibody specificities to become subsequently fixed due to a mechanism known as compensatory fixation (46) . Alternatively or in addition, it is possible that changes in HIV-1's neutralization sensitivity to PG9 and PG16 have occurred in the absence of direct selection pressure by PG9-and PG16-like antibodies on the antibody epitopes. The selection of longer V1 loops to obscure the access of the CD4 binding site to neutralizing antibodies may have had the coinciding effect of a decreased sensitivity of HIV-1 to neutralization by PG16.
Despite the increased resistance of HIV-1 to antibody neutralization at the population level, the newly identified BrNAbs PG9, PG16, and VRC01 display an extraordinary breadth and potency of neutralization toward currently circulating, recently transmitted subtype B HIV-1 variants. Together, these three BrNAbs were able to neutralize 87% of all virus variants from our cohort of contemporary seroconverters at concentrations below 1 g/ml. Another recently identified neutralizing antibody, HJ16 (10), was also tested but was found to have a very limited breadth of neutralization against HIV-1 variants from both historical and contemporary seroconverters (median IC 50 s, ϳ20 g/ml) and was therefore not included in this study. For PG9 and PG16, the percentage of viruses neutralized at a concentration of 1 g/ml in this study is concordant with the reported neutralizing activity of these BrNAbs against subtype B HIV-1 (50) . In contrast, VRC01 at an IC 50 of Յ1 g/ml neutralized a smaller proportion of virus variants in this study (33%) than of a previously analyzed panel of subtype B HIV-1 variants (80%) (52) . In the Wu et al. study (52) , the 80% neutralization sensitivity to VRC01 was tested in TZMbl cells with pseudoviruses, which are known to be more sensitive to neutralization than primary viruses in a PBMC-based assay (15) ; however, they also tested a smaller subtype B viral panel in a PMBC-based assay and found comparable neutralization sensitivities of VRC01 in these assays. This discrepancy may reflect the increased neutralization resistance of HIV-1 variants from contemporary seroconverters against VRC01 compared to that of virus variants from historical seroconverters, which may have been used by Wu et al. The overall neutralization sensitivity that was shown in our present study was for the HIV-1 variants from contemporary seroconverters only, as these are relevant for currently circulating strains. However, among HIV-1 variants of the historical seroconverters, the neutralization sensitivity to VRC01 was similar to that reported by Wu et al. However, it should be mentioned that an additional 30% of contemporary virus variants analyzed in this study were neutralized by VRC01 at antibody concentrations between 1 and 5 g/ml, indicating that a substantial proportion of relatively neutralization resistant HIV-1 variants from contemporary seroconverters are still sensitive to VRC01 neutralization, albeit at higher antibody concentrations. As we included only subtype B variants in our analyses, we cannot draw any conclusions about the activities of these three BrNAbs against other subtypes of HIV-1. In addition, although we observed the molecular changes that coincided with increased resistance to antibody neutralization over the calendar time of the epidemic in the envelopes of some non-clade B HIV-1 variants (7), it remains to be determined if and to what extent the neutralization resistance of non-subtype B HIV-1 has changed over the course of the epidemic. However, given the reported neutralization breadth of PG9, PG16, and VRC01 across different subtypes (50, 52) , it is likely that these BrNAbs continue to display broad and potent neutralizing activity against HIV-1 variants from different subtypes.
Compared to the newly identified BrNAbs PG9, PG16, and VRC01, the earlier-identified BrNAbs b12, 2G12, 2F5, and 4E10 conferred only moderate neutralization breadth and potency against currently circulating, recently transmitted HIV-1 variants. In concordance with previous studies, the BrNAbs targeting the MPER region in gp41, 2F5, and 4E10 showed the broadest neutralizing activity (23), while CD4 binding sitedirected BrNAb b12 was most narrow in its neutralizing capacity (30, 38) . These results seem to underscore the idea that the increased neutralization resistance of HIV-1 at the population level is specific for CD4 binding site-directed neutralizing activity, as we previously observed that the resistance to 2F5-and 2G12-mediated neutralization did not increase over time, while resistance to 4E10-mediated neutralization may even have decreased over time (7) .
Although levels of neutralization sensitivity were generally similar among viral variants from the same individual, substantial variation in the sensitivities to neutralization by certain antibodies was observed for viruses from some individuals. This was unexpected, as for each individual virus, variants were isolated from the same time point early after infection and showed limited sequence diversity (the diversity within gp120 sequences was Յ1.0%). Our finding may indicate that minor changes in the viral envelope may contribute to widely different neutralization sensitivities, which strengthens the idea that antibodies should be completely protective against infection, as changes that lead to neutralization resistance may occur even at a primary stage of infection. Indeed, in patients with acute HIV-1 infection, the immediate escape of transmitted/founder virus from autologous serum neutralization has been observed (3a) . In this study, viruses were isolated at the first visit after seroconversion for the historical patients, which was, on average, 1.4 months later than for viruses of the contemporary seroconverters. However, given the limited breadth of the earliest autologous neutralizing antibody responses, which are directed mainly against the variable regions of the viral envelope, it seems unlikely that this difference in sampling time points has had a major effect on the relative sensitivities of our viruses to neutralization by broadly neutralizing antibodies. Therefore, we think that although the viruses studied may not be identical to the transmitted or founder viruses in these individuals, their neutralization sensitivity may still be relevant to drawing conclusions about vaccine design.
In the absence of a correlate of protection, it remains unclear what antibody titers a vaccine should elicit to confer protection against HIV-1 infection. However, a potent antibody response with broadly neutralizing activity seems most desirable. Despite the increased neutralization resistance of HIV-1 to certain antibody specificities over the course of the epidemic, all viral variants tested in this study were sensitive to at least one BrNAb at concentrations below 5 g/ml. However, the antibody specificities that conferred the most potent neutralizing activity differed by virus variant, indicating that a vaccine against HIV-1 should most likely induce neutralizing antibodies that target various regions of the viral envelope in order to achieve maximum protection. The currently known BrNAb specificities may be sufficient to provide protection against all globally circulating HIV-1 variants, although it is likely that additional antibody specificities will be needed to tackle virus variants that are relatively resistant to the currently known BrNAbs. Fortunately, the screening of large cohorts for elite neutralizing activity has resulted in the identification of yet more potent BrNAbs, such as VRCPG04, which binds to the CD4 binding site and neutralizes with a breadth similar to that of VRC01 (23a). Furthermore, 13 additional antibodies have been isolated from the IAVI protocol G cohort, of which some have even greater potency and breadth than PG9 and PG16 (50a). With these newly emerging potent BrNAbs, still more epitopes which can potentially be included in a multivalent HIV-1 vaccine are being identified.
In conclusion, we have shown that HIV-1 has become increasingly resistant to CD4 binding site-directed antibodies, including the newly identified potent BrNAb VRC01, over the course of the epidemic and may also have evolved toward increased resistance to variable-loop-directed antibody PG16. However, despite the increased neutralization resistance, currently circulating HIV-1 strains were sensitive to multiple BrNAbs at low concentrations and, in particular, to the recently identified BrNAbs. In the face of a changing HIV-1 landscape over the course of 20 years, potent antibodies with exceptional neutralizing breadth are required to target multiple sites of the viral envelope in order to achieve sterilizing immunity.
